Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


Insmed reported $-154469000 in EBITDA for its fiscal quarter ending in March of 2023.

Ebitda Change
BioMarin Pharmaceutical BMRN:US USD 87.87M 87.82M
Gilead Sciences GILD:US USD 2.24B 456M
Insmed INSM:US USD -154469000 4.76M
Iveric bio Inc. OPHT:US USD -73771000 10.86M
Mirati Therapeutics MRTX:US USD -192748000 18.08M
Novartis NVS:US USD 4.72B 217M
Regeneron Pharmaceuticals REGN:US USD 1.1B 195.4M
Sarepta Therapeutics SRPT:US USD -126783000 30.5M
Seattle Genetics SGEN:US USD -136400000 297K
Ultragenyx Pharmaceutical RARE:US USD -148869000 8.2M
Vertex Pharmaceuticals VRTX:US USD 817.8M 254.1M